Mostrar el registro sencillo del ítem

dc.contributor.authorBenavides, M.
dc.contributor.authorDíaz-Rubio, E.
dc.contributor.authorCarrato, A.
dc.contributor.authorAbad, A.
dc.contributor.authorGuillén, C.
dc.contributor.authorGarcia-Alfonso, P.
dc.contributor.authorGil, S.
dc.contributor.authorCano, M. T.
dc.contributor.authorSafont, M. J.
dc.contributor.authorGravalos, C.
dc.contributor.authorManzano, J. L.
dc.contributor.authorSánchez, A.
dc.contributor.authorAlcaide, J.
dc.contributor.authorLópez López, Rafael 
dc.contributor.authorMassutí, B.
dc.contributor.authorSastre, J.
dc.contributor.authorMartínez, E.
dc.contributor.authorEscudero, P.
dc.contributor.authorMéndez, M.
dc.contributor.authorAranda, E.
dc.date.accessioned2021-09-29T12:43:12Z
dc.date.available2021-09-29T12:43:12Z
dc.date.issued2019
dc.identifier.issn2059-7029
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31803504es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15378
dc.description.abstractPurpose: Metastatic colorectal cancer (mCRC) is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumours driving varying prognosis. Methods: Patients with KRAS/RAS-wild type (wt) mCRC treated in first line with epidermal growth factor receptor inhibitors (EGFR-Is) (cetuximab or panitumumab) plus oxaliplatin or irinotecan-based chemotherapy from two phase II randomised trials conducted by the Spanish Cooperative for the Treatment of Digestive Tumours group were included in this retrospective study. The main objective was to analyse the prognostic effect of primary tumour location on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: Patients with KRAS-wt right-sided tumours (n=52) had significantly lower efficacy as compared with patients with KRAS-wt left-sided tumours (n=209); confirmed ORR (25% vs 47%, respectively; OR 0.4, 95% CI 0.2 to 0.8, p=0.004); and shorter median PFS (7.2 vs 9.9 months; HR 0.6, 95% CI 0.4 to 0.9, p=0.0157) and OS (13.6 vs 27.7 months; HR 0.5, 95% CI 0.3 to 0.7, p<0.0001). Similar results were observed in the RAS-wt populations. The further classification of left-sided tumours as colon or rectum delivered similar survival outcomes, as well as a tendency to diminished ORR in patients with rectum tumours. Conclusion: We observed significantly improved efficacy outcomes in patients with KRAS/RAS-wt mCRC treated with first-line EGFR-I plus chemotherapy in left-sided primary tumours as compared with right-sided primary tumours. Trial registration numbers: NCT01161316 and NCT00885885.en
dc.language.isoeng
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshMembrane Proteins*
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshGTP Phosphohydrolases*
dc.subject.meshTime Factors*
dc.subject.meshProto-Oncogene Proteins p21(ras)*
dc.subject.meshDisease Progression*
dc.subject.meshRetrospective Studies*
dc.subject.meshAged*
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols*
dc.subject.meshPrognosis*
dc.subject.meshAntineoplastic Agents*
dc.titleTumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trialses
dc.typeArtigoes
dc.authorsophosBenavides, M.
dc.authorsophosDíaz-Rubio, E.
dc.authorsophosCarrato, A.
dc.authorsophosAbad, A.
dc.authorsophosGuillén, C.
dc.authorsophosGarcia-Alfonso, P.
dc.authorsophosGil, S.
dc.authorsophosCano, M. T.
dc.authorsophosSafont, M. J.
dc.authorsophosGravalos, C.
dc.authorsophosManzano, J. L.
dc.authorsophosSánchez, A.
dc.authorsophosAlcaide, J.
dc.authorsophosLópez, R.
dc.authorsophosMassutí, B.
dc.authorsophosSastre, J.
dc.authorsophosMartínez, E.
dc.authorsophosEscudero, P.
dc.authorsophosMéndez, M.
dc.authorsophosAranda, E.
dc.identifier.doi10.1136/esmoopen-2019-000599
dc.identifier.pmid31803504
dc.identifier.sophos30592
dc.issue.number6es
dc.journal.titleESMO OPENes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médica
dc.page.initiale000599es
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890384/pdf/esmoopen-2019-000599.pdf
dc.rights.accessRightsopenAccess
dc.subject.decsproteínas protooncogénicas p21(ras)*
dc.subject.decspronóstico*
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada*
dc.subject.decsanciano*
dc.subject.decsGTP fosfohidrolasas*
dc.subject.decsproteínas de membranas*
dc.subject.decsestudios retrospectivos*
dc.subject.decsmediana edad*
dc.subject.decsfactores de tiempo*
dc.subject.decsadulto*
dc.subject.decsprogresión de la enfermedad*
dc.subject.decsantineoplásicos*
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number4es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 4.0 Internacional